FAST NEWS: Connect Biopharma Plunges Despite Positive Drug Trial Results
The latest: Connect Biopharma (CNTB.US) said on Tuesday its CBP-201 drug candidate achieved all primary and key secondary endpoints in the primary analysis population for a 16-week pivotal trial of…
FAST NEWS: Connect Biopharma Plunges on Poor Results for Colitis Drug
The latest: Connect Biopharma (CNTB.US) said late on Tuesday that results from a Phase 2 trial for its CBP-307 drug for treatment of patients with moderate to severe ulcerative colitis…
Connect Biopharma’s Latest Dermatitis Drug Update Fails to Pump Up Shares
Company’s stock sank after it released data on Phase 2b trials for its atopic dermatitis drug, a potential competitor to Regeneron-Sanofi blockbuster Dupixent Key takeaways: Loss-making Connect Biopharma says Phase…
RELATED ARTICLES
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK -
BRIEF: Everest unveils positive results for kidney drug EVER001 in Phase 1b/2a trial
1952.HK
- Pateo Connect revs up for IPO, belching widening losses and slumping margins
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Inmagene Bio charts backdoor to U.S. listing with offshore acquisition
IKNA.US
